26S proteasomes consist of cylindrical 20S proteasomes with 19S regulatory complexes attached to the ends. Treatment with high concentrations of salt causes the regulatory complexes to separate into two sub-complexes, the base, which is in contact with the 20S proteasome, and the lid, which is the distal part of the 19S complex. Here, we describe two assembly intermediates of the human regulatory complex. One is a dimer of the two ATPase subunits, Rpt3 and Rpt6. The other is a complex of nascent Rpn2, Rpn10, Rpn11, Rpn13, and Txnl1, attached to preexisting 20S proteasomes. This early assembly complex does not yet contain Rpn1 or any of the ATPase subunits of the base. Thus, assembly of 19S regulatory complexes takes place on preexisting 20S proteasomes, and part of the lid is assembled before the base.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jmb.2009.09.038 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Locating Polyubiquitin Receptors on the 19S Regulatory Proteasome of by Cross-Linking Mass Spectrometry.
J Am Soc Mass Spectrom
January 2025
Department of Molecular Biosciences, University of Texas, Austin, Texas 78712, United States.
The effectiveness of state-of-the-art cross-linking strategies and mass spectrometry (MS) detection was explored in an important biological context, namely, the ubiquitin-proteasome system, which is responsible for most of the regulated protein degradation in eukaryotic cells. The locations of possible binding sites on the 19S proteasome regulatory particle for Lys linked polyubiquitin chains were examined using cross-linking strategies and MS based detection by comparing two types of cross-linkers: a (bis)-sulfosuccinimidyl suberate (BS) and diethyl suberothioimidate (DEST). The well-established BS-based strategy produced 328 cross-linked peptides; however, no ubiquitin-19S cross-links were observed.
View Article and Find Full Text PDFPSMC2 promotes resistance against temozolomide in glioblastoma via suppressing JNK-mediated autophagic cell death.
Biochem Pharmacol
January 2025
School of Medical Science and Technology, Indian Institute of Technology Kharagpur, Kharagpur, India. Electronic address:
Temozolomide is universally used to treat glioblastoma due to its unique ability to cross the blood-brain barrier and inhibit tumor growth through DNA alkylation. However, over time, the inevitable emergence of resistance to temozolomide impedes successful treatment of this cancer. As a result, there is an urgent need to identify new therapeutic targets to improve treatment outcomes for this malignancy.
View Article and Find Full Text PDFRecombinant Expression of Photo-crosslinkable 26S Proteasome Base Subcomplex.
bioRxiv
December 2024
Department of Molecular and Cell Biology, University of California at Berkeley, Berkeley, CA 94720, USA.
The 26S proteasome complex is the hub for regulated protein degradation in the cell. It is composed of two biochemically distinct complexes: the 20S core particle with proteolytic active sites in an internal chamber and the 19S regulatory particle, consisting of a lid and base subcomplex. The base contains ubiquitin receptors and an AAA+ (ATPases associated with various cellular activities) motor that unfolds substrates prior to degradation.
View Article and Find Full Text PDFBoth 20S and 19S proteasome components are essential for meiosis in male mice.
Zool Res
January 2025
Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, Guangdong 510623, China. E-mail:
The proteasome, an evolutionarily conserved proteolytic complex comprising the 20S core particle and 19S regulatory particles, performs both shared and distinct functions across various tissues and organs. Spermatogenesis, a highly complex developmental process, relies on proteasome activity at multiple stages to regulate protein turnover. In this study, we selected the 20S subunit PSMA1 and 19S regulatory subunit PSMD2 to investigate the potential functions of the proteasome in spermatogenesis.
View Article and Find Full Text PDFA 2D detector array for relative dosimetry and beam steering for FLASH radiotherapy with electrons.
Med Phys
December 2024
Dosimetry for Radiotherapy, Physikalisch-Technische Bundesanstalt, Braunschweig, 38116, Germany.
Background: FLASH radiotherapy is an emerging treatment modality using ultra-high dose rate beams. Much effort has been made to develop suitable dosimeters for reference dosimetry, yet the spatial beam characteristics must also be characterized to enable computerized treatment planning, as well as quality control and service of a treatment delivery device. In conventional radiation therapy, this is commonly achieved by beam profile scans in a water phantom using a point detector.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!